ReShape Lifesciences Inc. (NasdaqCM:RSLS) will look for M&A. Paul Hickey President and Chief Executive Officer said during the Second Quarter 2021 Conference Call, "We remain committed to further evaluating the potential of this product, which is backed by a strong intellectual property portfolio through a nondilutive funding strategy. Finally, we will continue to evaluate M&A opportunities that align with our commitment to the physician-led weight loss and metabolic solutions market, specifically those that can enhance our current product portfolio and be accretive to our value".
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.162 USD | -4.59% | -2.88% | -35.08% |
04-12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
04-01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.08% | 3.98M | |
+8.37% | 219B | |
+6.46% | 183B | |
+10.60% | 133B | |
+25.15% | 108B | |
+0.27% | 63.06B | |
+12.00% | 52.02B | |
+3.96% | 48.2B | |
-0.14% | 40.37B | |
+14.94% | 39.35B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- ReShape Lifesciences to Seek M&A